Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units

Table 3 Mixed effects, generalised linear model for occurrence of ‘critical haemorrhage’ (intracranial haemorrhage or haemorrhage requiring transfusion matched for propensity for use of ‘enhanced’ prophylaxis

	Effect size (log odds)	p value	95% CI
(Intercept)	− 3.31	< 0.0001	− 4.41	− 2.21
Use of ‘enhanced’ (therapeutic) prophylaxis	0.187	0.64	− 0.591	0.964
Age (years)	− 3.57	0.1	− 7.85	0.713
BMI	− 0.83	0.41	− 2.79	1.13
History of hypertension	− 0.0719	0.86	− 0.879	0.736
History of diabetes	− 0.341	0.55	− 1.47	0.792
History of renal disease	− 0.374	0.73	− 2.52	1.77
Intubated	− 0.757	0.38	− 2.44	0.931
D-dimer at ICU_admission	− 7960	0.33	− 24,000	8070
P/F ratio at ICU admission	8.38	0.62	− 24.6	41.3
CRP at ICU admission	27.7	0.32	− 27	82.4
Fibrinogen at ICU_admission	− 89.9	0.14	− 210	30.2
Platelet count at_ICU_admission	2.71	0.91	− 44.6	50
WBC at ICU admission	2.11	0.039	0.11	4.12
Antiplatelet agent use	0.666	0.2	− 0.358	1.69

Effect sizes are unscaled log odds (positive indicates associate with increased risk of critical haemorrhage)
BMI, body mass index; ICU, intensive care unit; P/F partial pressure of oxygen/inspired fraction of oxygen; CRP, C-reactive protein; WBC, white blood cells

ISSN: 1364-8535